Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Atreca Inc BCEL

Alternate Symbol(s):  COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.


PINL:BCEL - Post by User

Bullboard Posts
Comment by TheHoboon Jan 14, 2011 10:24am
296 Views
Post# 17971812

RE: RE: beberebozo

RE: RE: beberebozoHere's some basic math for you Ruby (Don't worry I will keep it REAL simple for you.. You might need to close your mouth for a moment and breathe through your nose; but I promise that's the most you will need to do):

My ACB on CSI = 1.74
Even if CSI hit 7.00 = A difference of $5.26 a share.

If I had only one share of CSI, that means a profit of $5.26.. You still with me pumpkin? That means I would have made $5.26.

Now your shares in Outlook Resources (OLR) that halted are worth
.00.  No matter what way you look at it, you held a bag and lost miserably.

Hang in there pumpkin, this will blow your mind. $5.26 >
.00.  See what I did there?  In case you don't understand what ">" means, that's called "greater than".  Another way to look at it, anyone that's got shares in CSI > a fool in outlook resources (aka ruby7figures).

As a result, the common reaction of bagholders is indeed to run around slamming stocks that people have made money on (you know, instead of claiming to sell, then scrambling to call IR days later when it's halted and gone). hahaha.  Maybe a bit more baby duck is in order? Quack!
Bullboard Posts